Alternative Care in Patients With Auto-Immune Diseases

Auto-Immune Diseases Clinical Trial

— Alter-MAI  

Official title:

Proportion of the Use of Medicines and Alternative Care in Patients With Auto-Immune Diseases Alter-MAI

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04094259
• Other study ID #: 87RI19-0020 (ALTER-MAI)
• Status: Completed
• Start date: September 9, 2019
• Est. completion date: December 1, 2021

Study information

• Verified date: August 2022
• Source: University Hospital, Limoges
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Patients followed in Internal Medicine bring together favorable conditions for the use of alternative medicines. While some are recognized for their benefits, some can, on the contrary, harm the patient. It is therefore proposed to make a complete descriptive inventory of these practices, through an anonymized questionnaire. The main objective is the evaluation of the proportion of the use of alternative medicines in patients with in the department of Internal Medicine A

Description:

Patients followed in Internal Medicine department bring together favorable conditions for the use of alternative medicines. While some are recognized for their benefits, some can, on the contrary, harm the patient. It is therefore proposed to make a complete descriptive inventory of these practices, through an anonymized questionnaire. The main objective is the evaluation of the proportion of the use of alternative medicines in patients with autoimmune diseases in the department of Internal Medicine .

At all times alternative medicine has existed. Internal Medicine deals with rare autoimmune diseases, of which there is not always a cure. Even when the treatment is optimal, there are often subjective complaints.Patients followed in Internal Medicine therefore have favorable conditions for the use of alternative medicines. While some are recognized for their benefits, some can, on the contrary, harm the patient. It is therefore proposed to make a complete descriptive inventory of these practices, through an anonymized questionnaire. This information will make it possible to target the patient's needs, and to be able to offer alternative medicines that are better focused, without calling into question their conventional treatment

Recruitment information / eligibility

• Status: Completed
• Enrollment: 121
• Est. completion date: December 1, 2021
• Est. primary completion date: December 1, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion criteria:

• Patient with systemic lupus erythematosus (ARA and/or SLICC criteria) OR with primary Sjögren's syndrome (revised Americano European criteria) OR with systemic scleroderma (ACR/EULAR 2012 criteria)

• Patient with signed consent

Exclusion criteria:

• Patients deprived of their liberty

• Minors and adults subject to legal protection measures

• Patients subject to a justice safeguard measure

• Patient unable to understand or adhere to the protocol

Related Conditions & MeSH terms

• Auto-Immune Diseases
• Autoimmune Diseases
• Immune System Diseases

Intervention

Behavioral:
• Questionnaire.
patients will respond to a specific questionnaire regarding the use of alternative medicine

Locations

Country	Name	City	State
France	Médecin Interne A	Limoges

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Limoges

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The number of patients using alternative medicine.	Counting the number of patients using alternative medicine.	At day 1